Half a Century of Antidepressant Drugs

López‐Muñoz, Francisco; Álamo, Cecilio; Juckel, Georg; Assion, Hans‐Jörg

doi:10.1097/jcp.0b013e3181bb617

Cited by 72 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibition of MAO activity promotes an increase in monoamines and is one important target for the treatment of depression. Monoamine oxidase inhibitors have been used for decades in the treatment of depression and their antidepressant properties result from selective MAO-A inhibition in the central nervous system, which could lead to increased brain levels of 5-HT, NE, and DA [42, 43]. Recently, selegiline, an MAO-B inhibitor, has been used with success in the treatment of patients that are refractory to other antidepressant in a pharmaceutical transdermal preparation to avoid food interactions [44, 45].…”

Section: Discussionmentioning

confidence: 99%

Antidepressant-Like Effect ofIlex paraguariensisin Rats

Reis¹,

Neto

Cattani

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

In this study, we investigated the possible antidepressant-like effect of I. paraguariensis in rats. Rats were treated for four weeks with an aqueous extract of I. paraguariensis in drinking water, following the traditional preparation of this beverage. After the period of treatment, behavioral (elevated plus-maze, open field test, and forced swimming test) and biochemical parameters (lipid peroxidation assay, thiol content, vitamin C levels, and monoamine oxidase activity) were evaluated. Animals were also analyzed on forced swimming test after 24 hours of I. paraguariensis intake. An additional group was injected with selegiline 24 hours and 30 minutes before forced swimming test as positive control. HPLC analysis revealed the profile of I. paraguariensis extract. I. paraguariensis reduced the immobility time on forced swimming test without significant changes in locomotor activity in the open field test. Any anxiolytic/anxiogenic effect of I. paraguariensis was observed in rats through the elevated plus-maze test. The antidepressant-like effect of I. paraguariensis was not accompanied by inhibitory effect on monoamine oxidase activity. There were no significant alterations on lipid peroxidation, thiol content, and vitamin C levels among the groups. In conclusion, aqueous extract of I. paraguariensis decreases the time of immobility in rats suggesting an antidepressant-like effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Antidepressant-Like Effect ofIlex paraguariensisin Rats

Reis¹,

Neto

Cattani

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Chemists at Hoffmann-La Roche Ltd USA had developed isonicotinyl hydrazide (isoniazid) for the treatment of tuberculosis and isoniazid proved to be a successful antitubercular compound as the mortality rate of tuberculosis significantly decreased after the drug had been on the market for only one year (Lopez-Munoz, Alamo, Juckel, & Assion, 2007; Pletscher, 1991). While developing new antitubercular compounds, Fox and Gibas (1953) synthesized isopropyl-isonicotinyl hydrazide (iproniazid), a monoalkyl derivative of isoniazid, which would later serve as a catalyst for pharmacological treatment of MDD.…”

Section: Monoamine Hypothesis and Monoamine Based Pharmacological Trementioning

confidence: 99%

“…Clinical observations reported marked “side effects” of iproniazid in patients being treated for tuberculosis, which included euphoria, psychostimulation, increased appetite, and improved sleep. The “side effects” produced by iproniazid were not originally identified as therapeutic effects because these side effects were not consistent across studies (Lopez-Munoz et al, 2007; Pletscher, 1991). Loomer, Saunders, and Kline (1958) conducted a systematic clinical study on patients with depression, in which the patients were treated with iproniazid for several weeks.…”

Section: Monoamine Hypothesis and Monoamine Based Pharmacological Trementioning

confidence: 99%

“…One example of the safety concern was termed the “cheese reaction.” The combination of foods containing high amounts of tyramine, such as cheese or dairy products, and MAO inhibitors, which increase concentrations of tyramine and norepinephrine in the sympathetic nervous system, would lead to increased heart rate, hypertension and sweating. It was later determined that inhibiting MAO A was functionally involved in the antidepressant effects of MAO inhibitors (Lopez-Munoz et al, 2007; Shulman et al, 2013). …”

Section: Monoamine Hypothesis and Monoamine Based Pharmacological Trementioning

confidence: 99%

See 1 more Smart Citation

A brief history of the development of antidepressant drugs: From monoamines to glutamate.

Hillhouse

Porter

2015

Experimental and Clinical Psychopharmacology

405

243

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States. It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacological treatment for MDD was discovered. Several monoamine-based pharmacological drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved. As a result of a “proof-of-concept” study in 2000 with the noncompetitive NMDA antagonist ketamine, a number of studies have examined the glutamatergic systems as viable targets for the treatment of MDD. This review will provide a brief history on the development of clinically available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiology of MDD. Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD. The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD. However, compounds that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clinical trials. Thus, the clinical findings to date are encouraging and support the continued search for and the development of novel compounds that target glutamatergic mechanisms.

show abstract

“…One of the most popular hydrazides is isonicotinic acid hydrazide (INH), an antituberculosis agent that has been clinically applied and marketed under the name isoniazid (1). Isocarboxazid is commonly used as an antidepressant (2). Other hydrazides serve as agricultural herbicides, pesticides, insecticides, fungicides, or plant growth regulators (3).…”

mentioning

confidence: 99%

Hydrazidase, a Novel Amidase Signature Enzyme That Hydrolyzes Acylhydrazides

et al. 2015

View full text Add to dashboard Cite

The degradation mechanisms of natural and artificial hydrazides have been elucidated. Here we screened and isolated bacteria that utilize the acylhydrazide 4-hydroxybenzoic acid 1-phenylethylidene hydrazide (HBPH) from soils. Physiological and phylogenetic studies identified one bacterium as Microbacterium sp. strain HM58-2, from which we purified intracellular hydrazidase, cloned its gene, and prepared recombinant hydrazidase using an Escherichia coli expression system. The Microbacterium sp. HM58-2 hydrazidase is a 631-amino-acid monomer that was 31% identical to indoleacetamide hydrolase isolated from Bradyrhizobium japonicum. Phylogenetic studies indicated that the Microbacterium sp. HM58-2 hydrazidase constitutes a novel hydrazidase group among amidase signature proteins that are distributed within proteobacteria, actinobacteria, and firmicutes. The hydrazidase stoichiometrically hydrolyzed the acylhydrazide residue of HBPH to the corresponding acid and hydrazine derivative. Steady-state kinetics showed that the enzyme hydrolyzes structurally related 4-hydrozybenzamide to hydroxybenzoic acid at a lower rate than HBPH, indicating that the hydrazidase prefers hydrazide to amide. The hydrazidase contains the catalytic Ser-Ser-Lys motif that is conserved among members of the amidase signature family; it shares a catalytic mechanism with amidases, according to mutagenesis findings, and another hydrazidase-specific mechanism must exist that compensates for the absence of the catalytic Ser residue. The finding that an environmental bacterium produces hydrazidase implies the existence of a novel bacterial mechanism of hydrazide degradation that impacts its ecological role.

show abstract

Half a Century of Antidepressant Drugs

Cited by 72 publications

References 34 publications

Antidepressant-Like Effect ofIlex paraguariensisin Rats

Antidepressant-Like Effect ofIlex paraguariensisin Rats

A brief history of the development of antidepressant drugs: From monoamines to glutamate.

Hydrazidase, a Novel Amidase Signature Enzyme That Hydrolyzes Acylhydrazides

Contact Info

Product

Resources

About